Omega-3

Verify with FDA CVM →

115 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
115
Total Reports
11
Deaths Reported
960.0%
Death Rate

Active Ingredients

Omega-3

Administration Routes

UnknownOral

Species Affected

Dog 112
Cat 3

Most Affected Breeds

Retriever - Labrador 16
Shepherd Dog - German 5
Retriever - Golden 5
Terrier - Yorkshire 5
Schnauzer - Miniature 4
Boxer (German Boxer) 4
Shih Tzu 3
Dachshund - Miniature 3
Shepherd Dog - Australian 3
Terrier (unspecified) 3

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 15
Lack of efficacy - NOS 13
Vomiting 12
INEFFECTIVE, LOSS OF EFFECT 12
Diarrhoea 11
INEFFECTIVE, ATOPY CONTROL 11
Anorexia 10
Elevated alanine aminotransferase (ALT) 10
Behavioural disorder NOS 9
Elevated serum alkaline phosphatase (SAP) 7
Elevated creatinine 7
Other abnormal test result NOS 7

Outcome Breakdown

Ongoing
68 (59.1%)
Outcome Unknown
22 (19.1%)
Recovered/Normal
14 (12.2%)
Euthanized
6 (5.2%)
Died
5 (4.3%)

Data Summary

Metric Value
Total adverse event reports 115
Reports involving death 11
Case-fatality rate (reported events) 960.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Omega-3 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 115 adverse event reports referencing Omega-3, including 11 reports in which the animal died — a 960.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Omega-3. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Omega-3 reports are Dog (112 reports), Cat (3 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (16), Shepherd Dog - German (5), Retriever - Golden (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Omega-3 are Lethargy (see also Central nervous system depression in 'Neurological') (15), Lack of efficacy - NOS (13), Vomiting (12), INEFFECTIVE, LOSS OF EFFECT (12). Of the 115 reports with a coded outcome, Ongoing is the leading category at 59.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Omega-3.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial